Back to journals
Academic JournalOpen Access

International Journal of Neuropsychopharmacology

28 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 28 psychedelic papers Blossom tracks from International Journal of Neuropsychopharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does International Journal of Neuropsychopharmacology carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

5papers published in 2021

+67% vs 2020

19 published by 2021

Browse papers→

Don't read as the journal's total output: only the 28 of 28 tracked psychedelic papers from International Journal of Neuropsychopharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does International Journal of Neuropsychopharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
16
Neuroimaging & Brain Measures
10
Anxiety Disorders
5
Suicidality
5
Safety & Risk Management
5
Schizophrenia
4
PTSD
4
Interpersonal Functioning & Social Connectedness
3
Other
19

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does International Journal of Neuropsychopharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ketamine
12
MDMA
5
Esketamine
4
Ayahuasca
4
LSD
4
Psilocybin
4
Salvia Divinorum
2
Mescaline
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

International Journal of Neuropsychopharmacology has 28 tracked papers indexed in Blossom (2013–2025) from 222 authors, most often covering Ketamine, MDMA and Esketamine, across Depressive Disorders, Healthy Volunteers and Neuroimaging & Brain Measures.

Published Papers

Open Accessindividual

Safety and Efficacy with Esketamine in Treatment-Resistant Depression: Long-Term Extension Study

In the phase 3 SUSTAIN-3 long-term extension (1,148 patients, 3,777 patient‑years), intermittent intranasal esketamine plus an oral antidepressant showed no new safety signals and an adverse event profile consistent with earlier studies. Depression severity improved during induction and was generally maintained during optimisation/maintenance, with remission in 35.6% at induction and about 48–50% at week 112/maintenance endpoint.

Published
Journal
International Journal of Neuropsychopharmacology
Authors
Zaki, N., Chen, N. )., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Young, A. H., Chb, M. B., Lacerda, A. L. T., Paik, J. W., Popova, V., Fu, D. J.
Open Accessindividual

Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants: A Randomized Controlled Trial

This secondary analysis of an RCT (n=31) evaluates a novel pharmaceutical formulation of DMT and harmine in healthy male volunteers. The study finds that intranasal DMT and buccal harmine (pharmahuasca) produce consistent pharmacokinetic profiles and safe, well-tolerated effects resembling ayahuasca, with subjective experiences lasting 2-3 hours. This formulation is proposed as a safer, standardised alternative for potential therapeutic use in mental health disorders.

Published
Journal
International Journal of Neuropsychopharmacology
Authors
Mueller, J., Mueller, M. J., Aicher, H. D., Dornbierer, D. A., Marten, L., Suay, D., Meling, D., Elsner, C., Wicki, I., Poetzsch, S. N., Caflisch, L., Hempe, A., Steinhart, C., Puchkov, M., Kost, J., Landolt, H-P., Seifritz, E., Quednow, B. B., Scheidegger, M.
Open Accessindividual

Chronic 3,4-Methylenedioxymethamphetamine (MDMA) use is related to glutamate and GABA concentrations in the striatum, but not in the anterior cingulate cortex

Chronic MDMA users showed elevated glutamate–glutamine (GLX) in the left striatum but not in the medial anterior cingulate cortex (ACC), and although overall GABA did not differ by group, striatal GABA was negatively associated with MDMA use frequency. GLX estimates from MEGA-PRESS were more robust than short–echo-time PRESS, suggesting MDMA-related striatal glutamatergic and GABAergic alterations that may contribute to cognitive deficits.

Published
Journal
International Journal of Neuropsychopharmacology
Authors
Zimmermann, J., Zölch, N., Coray, R., Bavato, F., Friedli, N., Baumgartner, M. R., Steuer, A. E., Opitz, A., Werner, A., Oeltzschner, G., Seifritz, E., Stock, A. K., Beste, C., Cole, D. M., Quednow, B. B.
Open Accessindividual

A Randomized Double-Blind Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation

In this randomized double‑blind trial of 84 outpatients with treatment‑resistant depression and prominent suicidal ideation, a single low‑dose ketamine infusion (35mg/70kg) produced greater antidepressant effects than midazolam lasting up to 14 days and antisuicidal effects lasting about 5 days. Benefits were most evident in patients whose current episode was under 24 months or who had failed ≤4 antidepressants, and the infusion was safe and well tolerated.

Published
Journal
International Journal of Neuropsychopharmacology
Authors
Su, T. P., Li, C. T., Lin, W. C., Wu, H. J., Tsai, S. J., Bai, Y. M., Mao, W. C., Tu, P. C., Chen, L. F., Li, W. C., Chen, M. H.
Open Accessindividual

Spectral changes of EEG following a 6-week low-dose oral ketamine treatment in adults with major depressive disorder and chronic suicidality

In adults with major depressive disorder and chronic suicidality, a 6‑week low‑dose oral ketamine regimen produced a transient reduction in centro‑parietal alpha power immediately post‑treatment that returned toward baseline by four‑week follow‑up, while theta and low‑beta bands showed delayed changes emerging after treatment cessation. Decreases in occipital theta correlated with improvements in depression and stress scores, suggesting EEG spectral shifts may track clinical response.

Published
Journal
International Journal of Neuropsychopharmacology
Authors
Lagopoulos, J.
Open Accessindividual

Adverse Events and Measurement of Dissociation after the First Dose of Esketamine in Patients with TRD

In patients with treatment‑resistant depression given a first dose of esketamine, dissociation was reported in 14.3% and CADSS item scores generally increased with investigator‑reported dissociation severity but showed substantial variability. No CADSS cutoff reliably discriminated presence versus absence of investigator‑reported dissociation, and psychotic symptoms were uncommon.

Published
Journal
International Journal of Neuropsychopharmacology
Authors
Williamson, D., Turkoz, I., Wajs, E., Singh, J. B., Borentain, S., Drevets, W. C.

Quick Facts

Papers Indexed
28
h-Index
130
Open Access
Yes
Publisher
Oxford University Press
Country
United Kingdom
Website
Visit